Pfizer Expands NURTEC ODT Migraine Program with Korean Real-World Study and New Tablet Formulation
核心洞察
Pfizer is launching a post-marketing observational study in Korea to track real-world safety and effectiveness of NURTEC ODT 75 mg in adults with migraine (搜索), as required by Korean regulators.
The company is simultaneously conducting a Phase 1 bioequivalence study comparing a new ODT2 test formulation against the existing orally disintegrating tablet to support product line optimization.
Both studies represent Pfizer's strategic efforts to expand NURTEC's footprint in Asia and enhance lifecycle management of its CGRP receptor (搜索) antagonist migraine (搜索) portfolio.
Pfizer Inc. is advancing its migraine (搜索) treatment portfolio through two complementary clinical initiatives focused on NURTEC ODT, the company's CGRP receptor (搜索) antagonist containing rimegepant sulfate. The pharmaceutical giant is launching a post-marketing study in Korea while simultaneously conducting bioequivalence testing for a new tablet formulation.
Korean Real-World Evidence Study
Pfizer is initiating an observational post-marketing study in Korea to evaluate the real-world safety and effectiveness of NURTEC ODT 75 mg in adults with migraine (搜索). The study aims to assess how the drug performs outside controlled clinical trials, fulfilling requirements set by Korean regulatory authorities.
The observational design means physicians will not randomly assign patients or compare against control medications. Instead, researchers will prospectively follow patients who already receive NURTEC ODT in routine clinical care and record outcomes over time. NURTEC ODT serves dual purposes as both an acute treatment to stop migraine (搜索) attacks and a preventive therapy for episodic migraines.
The study was first submitted on February 28, 2026, with the latest update filed on May 12, 2026. Current status remains "not yet recruiting," indicating that site activation and patient enrollment are pending.
Phase 1 Bioequivalence Study
Concurrently, Pfizer is preparing a Phase 1 bioequivalence study titled "A PHASE 1, OPEN LABEL, SINGLE DOSE, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF TWO FORMULATIONS OF A CGRP RECEPTOR (搜索) ANTAGONIST IN HEALTHY ADULT PARTICIPANTS."
The trial will compare blood levels between an ODT2 test formulation and the existing orally disintegrating tablet reference standard. Both formulations contain the same CGRP receptor (搜索) blocker, with the study designed to confirm that the new tablet dissolves and absorbs similarly to the currently approved version.
The randomized crossover design means healthy adult participants will receive both formulations in different sequences. As an open-label study without blinding, the primary objective focuses on demonstrating similar drug exposure rather than testing clinical benefits or safety in patients.
Study documentation was first submitted on May 12, 2026, with the most recent update on May 19, 2026. While planning remains active, recruitment has not yet commenced, and completion dates have not been posted.
Strategic Implications
These initiatives support Pfizer's broader strategy to expand NURTEC's presence in Asian markets while optimizing the product through lifecycle management. The Korean real-world study could provide valuable safety and effectiveness data that may strengthen regional pricing negotiations and competitive positioning against other CGRP migraine (搜索) therapies from companies like AbbVie (搜索) and Eli Lilly.
The bioequivalence study represents product optimization efforts that could support a more flexible formulation portfolio rather than development of an entirely new therapeutic entity. Such lifecycle management approaches can help extend revenue streams for existing assets in the competitive CGRP migraine (搜索) treatment landscape.
Both studies remain in startup phases, with investors able to track progress through the ClinicalTrials.gov portal as enrollment and data collection advance.